Literature DB >> 25935643

N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation.

Xiang Zhou1, Ella J Born2, Cheryl Allen3, Sarah A Holstein3, David F Wiemer4.   

Abstract

The N-oxide derivatives of [2-(3-pyridinyl)-1-hydroxyethylidene-1,1-phosphonocarboxylic acid (or PEHPC) and [2-(3-pyridinyl)-1-ethylidene-1,1-phosphonocarboxylic acid (or PEPC) have been prepared and evaluated for their activity against several enzymes which utilize isoprenoids. The parent pyridines are known inhibitors of GGTase II, but the N-oxide derivatives show no improvement in biological activity in assays with the isolated enzyme. However, the PEHPC N-oxide did induce significant accumulation of intracellular light chain in myeloma cells, consistent with inhibition of Rab geranylgeranylation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Bioassay; GGTase II; Myeloma; Pyridyl N-oxides; Rab GGTase

Mesh:

Substances:

Year:  2015        PMID: 25935643      PMCID: PMC4462192          DOI: 10.1016/j.bmcl.2015.04.021

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

Review 1.  The relationship between the chemistry and biological activity of the bisphosphonates.

Authors:  Frank H Ebetino; Anne-Marie L Hogan; Shuting Sun; Maria K Tsoumpra; Xuchen Duan; James T Triffitt; Aaron A Kwaasi; James E Dunford; Bobby L Barnett; Udo Oppermann; Mark W Lundy; Alan Boyde; Boris A Kashemirov; Charles E McKenna; R Graham G Russell
Journal:  Bone       Date:  2011-04-09       Impact factor: 4.398

2.  Structure-guided development of selective RabGGTase inhibitors.

Authors:  Robin S Bon; Zhong Guo; E Anouk Stigter; Stefan Wetzel; Sascha Menninger; Alexander Wolf; Axel Choidas; Kirill Alexandrov; Wulf Blankenfeldt; Roger S Goody; Herbert Waldmann
Journal:  Angew Chem Int Ed Engl       Date:  2011-04-21       Impact factor: 15.336

Review 3.  Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis.

Authors:  Ranuccio Nuti
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

4.  Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.

Authors:  Fraser P Coxon; Frank H Ebetino; Emilie H Mules; Miguel C Seabra; Charles E McKenna; Michael J Rogers
Journal:  Bone       Date:  2005-09       Impact factor: 4.398

5.  Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Leuk Res       Date:  2010-09-09       Impact factor: 3.156

6.  Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives.

Authors:  M Takeuchi; S Sakamoto; K Kawamuki; H Kurihara; H Nakahara; Y Isomura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1998-11       Impact factor: 1.645

7.  Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds.

Authors:  Masaru Watanabe; Hannah D G Fiji; Lea Guo; Lai Chan; Sape S Kinderman; Dennis J Slamon; Ohyun Kwon; Fuyuhiko Tamanoi
Journal:  J Biol Chem       Date:  2008-01-28       Impact factor: 5.157

8.  Triazole-based inhibitors of geranylgeranyltransferase II.

Authors:  Xiang Zhou; Sara V Hartman; Ella J Born; Jacqueline P Smits; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

9.  Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells.

Authors:  E J Born; S V Hartman; S A Holstein
Journal:  Blood Cancer J       Date:  2013-12-06       Impact factor: 11.037

10.  Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase.

Authors:  Rudi A Baron; Richard Tavaré; Ana C Figueiredo; Katarzyna M Błazewska; Boris A Kashemirov; Charles E McKenna; Frank H Ebetino; Adam Taylor; Michael J Rogers; Fraser P Coxon; Miguel C Seabra
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

View more
  2 in total

Review 1.  Targeting prenylation inhibition through the mevalonate pathway.

Authors:  Pimyupa Manaswiyoungkul; Elvin D de Araujo; Patrick T Gunning
Journal:  RSC Med Chem       Date:  2019-12-23

2.  P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.

Authors:  Ari Hashimoto; Tsukasa Oikawa; Shigeru Hashimoto; Hirokazu Sugino; Ayumu Yoshikawa; Yutaro Otsuka; Haruka Handa; Yasuhito Onodera; Jin-Min Nam; Chitose Oneyama; Masato Okada; Mitsunori Fukuda; Hisataka Sabe
Journal:  J Cell Biol       Date:  2016-04-04       Impact factor: 10.539

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.